on OXURION (EBR:OXUR)
Oxurion General Meeting Postponed
Leuven, Belgium – Oxurion NV, the Belgian biopharmaceutical company listed on Euronext Brussels under the symbol OXUR, has announced the postponement of its Annual General Meeting. Originally scheduled, this meeting is now scheduled for May 13, 2025. The reason given is the incomplete completion of the annual accounts due to administrative reasons.
Oxurion specializes in the development of innovative ophthalmic therapies to treat retinal diseases. Located in Leuven, it continues to make advances in this field.
The press release also addressed forward-looking statements, which are subject to various risks and uncertainties, and clarified that this did not constitute an offer to sell securities.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all OXURION news